C

Christian Medical College | Pulmonary Medicine

Research site

(Unclaimed)

Location

Christian Medical College,Ida Scudder Road,, Vellore, Tamil Nadu, India

Site insights

Top conditions

Top treatments

Empagliflozin

BI 690517

Docetaxel

Capsaicin

Milvexian

Doxorubicin

Nintedanib

Bevacizumab

Tenofovir

Zidovudine

Parent organization

This site is a part of Christian Medical College

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 67 total trials

Locations recently updated

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

The main aim of this study is to find out how well elritercept works in lowering the need for RBC transfusions. Other aims are to learn how well elri...

Enrolling

Myelodysplastic Syndromes

Drug: Placebo

Drug: Elritercept

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.

Enrolling

Ischemic Stroke; Ischemic Attack, Transient

Drug: Placebo

Drug: Milvexian

A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)

Part 1 (dose escalation) will evaluate the safety and tolerability of 2 doses (100 milligrams/kilogram \[mg/kg\] and 200 mg/kg) of eteplirsen in appr...

Active, not recruiting

Muscular Dystrophy, Duchenne

Drug: Eteplirsen

Atrasentan in Patients With IgA Nephropathy (ALIGN)

The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA...

Active, not recruiting

Immunoglobulin A Nephropathy

IgA Nephropathy

Drug: Placebo

Drug: Atrasentan

Locations recently updated

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study....

Enrolling

Kidney Disease, Chronic

Drug: Placebo matching BI 690517

Drug: Empagliflozin